Literature DB >> 14506772

Molecular epidemiology of malaria in Cameroon. XV. Experimental studies on serum substitutes and supplements and alternative culture media for in vitro drug sensitivity assays using fresh isolates of Plasmodium falciparum.

Leonardo K Basco1.   

Abstract

In vitro drug sensitivity assay is an important tool for various on-going studies aiming to establish the correlation between candidate molecular markers for drug resistance and drug response in laboratory-adapted strains and field isolates of Plasmodium falciparum. A widespread use of this technique in the field would require a suitable substitute that can replace human serum. In this study, several alternative sources of serum substitutes and supplements were evaluated for their capacity to sustain parasite growth for a single life cycle and their compatibility with in vitro assays for clinical isolates that have not been adapted to in vitro culture. Albumax, a commercial preparation of lipid-enriched bovine albumin, did not support parasite growth as much as human serum and fetal calf serum in several isolates. Other serum supplements (AmnioMax and Ultroser) supported parasite growth relatively well. The 50% inhibitory concentrations (IC50s) of chloroquine and antifolates determined with 0.05% Albumax were generally two or three times higher than with human serum. With 10% fetal calf serum, IC50s for chloroquine and antifolates were approximately two times higher and three times lower than with human serum, respectively. The use of AmnioMax and OptiMAb resulted in a greater than two-fold increase in IC50s and several uninterpretable assays. Despite possible batch-to-batch differences, fetal calf serum may be a suitable substitute for in vitro drug assays while awaiting the results of further studies on other serum substitutes and supplements.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14506772

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  4 in total

1.  Comparison of a SYBR green I-based assay with a histidine-rich protein II enzyme-linked immunosorbent assay for in vitro antimalarial drug efficacy testing and application to clinical isolates.

Authors:  David J Bacon; Christine Latour; Carmen Lucas; Olga Colina; Pascal Ringwald; Stéphane Picot
Journal:  Antimicrob Agents Chemother       Date:  2007-01-12       Impact factor: 5.191

2.  In vitro adaptability of Plasmodium falciparum to different fresh serum alternatives.

Authors:  Chandrajit Dohutia; Pradyumna K Mohapatra; Dibya Ranjan Bhattacharyya; Kabita Gogoi; Khukumoni Bora; Basanta K Goswami
Journal:  J Parasit Dis       Date:  2016-06-30

3.  World Antimalarial Resistance Network (WARN) II: in vitro antimalarial drug susceptibility.

Authors:  David J Bacon; Ronan Jambou; Thierry Fandeur; Jacques Le Bras; Chansuda Wongsrichanalai; Mark M Fukuda; Pascal Ringwald; Carol Hopkins Sibley; Dennis E Kyle
Journal:  Malar J       Date:  2007-09-06       Impact factor: 2.979

4.  Analysis of ex vivo drug response data of Plasmodium clinical isolates: the pros and cons of different computer programs and online platforms.

Authors:  Grennady Wirjanata; Irene Handayuni; Sophie G Zaloumis; Ferryanto Chalfein; Pak Prayoga; Enny Kenangalem; Jeanne Rini Poespoprodjo; Rintis Noviyanti; Julie A Simpson; Ric N Price; Jutta Marfurt
Journal:  Malar J       Date:  2016-03-02       Impact factor: 2.979

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.